RxDoctor Payments Data

Heidi Johnson, NP

Family · Weaverville, CANPI 1033695184

Payments from drug & device makers

$842in general payments, 2019–2025

Across 45 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$323
  • Lilly USA, LLC$85
  • GSK$80
  • Indivior Inc.$63
  • AstraZeneca$58
  • Ultragenyx Pharmaceutical Inc.$50
  • plus $183 from 9 others

What the payments were for

  • Food & beverage$842100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$842 in reported general payments places this provider in the 70th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$80,166
Medicare patients
370
Services billed
1,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter127$109,224
JardianceEmpagliflozin91$106,411
TrulicityDulaglutide81$93,589
OzempicSemaglutide89$93,535
FarxigaDapagliflozin Propanediol88$74,669
EliquisApixaban64$73,840
MounjaroTirzepatide57$71,409
XareltoRivaroxaban27$35,831
RybelsusSemaglutide16$31,200
Albuterol Sulfate HfaAlbuterol Sulfate225$11,633
Emgality PenGalcanezumab-Gnlm11$11,199
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,634
SynjardyEmpagliflozin/Metformin Hcl16$10,446
Breo ElliptaFluticasone/Vilanterol28$10,360
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$9,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$85$164,998138 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$80$136,387194 claims
AstraZenecaFarxiga, Breztri Aerosphere, Pulmicort Flexhaler$58$87,696117 claims
PfizerEliquis$11$73,84064 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,634 family providers in California.

Other family in Weaverville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →